FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly to pharmaceutical treatment of atherosclerosis and an associated risk of cardiovascular diseases. That is ensured by using the effective amount of a Syk-kinase inhibitor representing N4-(2,2-dimethyl-4-[(dihydrophosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluor-K2-(3,4,5-trimethoxyphenyl)-2,4-diamonopyrimidines and a salt thereof.
EFFECT: method provides the substantial size reduction of the atherosclerotic involvements, particularly of the aortic root and arch.
5 ex, 2 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES BY MEANS OF 2,4-PYRIMIDINDIAMIN COMPOUNDS | 2003 |
|
RU2376992C2 |
| PRODRUGS OF 2,4-PYRIMIDINE DIAMINE COMPOUNDS AND USE THEREOF | 2006 |
|
RU2416616C2 |
| 2,4-PYRIMIDINDIAMINE COMPOUNDS HAVING EFFECT IN CASE OF AUTOIMMUNE DISORDERS | 2004 |
|
RU2356901C2 |
| COMPOSITIONS AND METHODS FOR JAK PATH INHIBITION | 2010 |
|
RU2557982C2 |
| METHODS FOR TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH USE OF 2,4-PYRIMIDINEDIAMINE | 2013 |
|
RU2659777C2 |
| COMPOSITIONS AND METHODS FOR JAK PATH INHIBITION | 2011 |
|
RU2672100C2 |
| NOVEL CHEMICAL COMPOUNDS - 2,4-DIAMINO-1,3,5-TRIAZINE DERIVATIVES FOR PREVENTING AND TREATING HUMAN AND ANIMAL DISEASES | 2012 |
|
RU2509770C2 |
| NEW CRYSTALLINE SALT FORM OF 2,2-DIMETHYL-6-((4-((3,4,5-TRIMETHOXYPHENYL)AMINO)-1,3,5-TRIAZIN-2-YL)AMINO)-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE FOR MEDICAL USE | 2016 |
|
RU2621187C1 |
| XINAFOATE SALT OF N4-[(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ON)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYL METHYLENEOXY)PHENYL]-2,4-PYRIMIDINE DIAMINE | 2008 |
|
RU2458925C2 |
| KINASE INHIBITORS | 2007 |
|
RU2440352C2 |
